$13.62
0.37% yesterday
NYSE, Nov 15, 10:10 pm CET
ISIN
US8740602052
Symbol
TAK
Sector
Industry

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Target price 2024 - Analyst rating & recommendation

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Classifications & Recommendation:

Buy
43%
Hold
57%

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Price Target

Target Price $15.63
Price $13.62
Potential
Number of Estimates 12
12 Analysts have issued a price target Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2025 . The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR target price is $15.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 6 Analysts recommend Takeda Pharmaceutical Co. Ltd. Sponsored ADR to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock has an average upside potential 2025 of . Most analysts recommend the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Revenue Billion $ 29.49 29.34
0.78% 0.49%
EBITDA Margin 29.51% 25.16%
10.15% 14.73%
Net Margin 3.44% 2.81%
57.00% 18.33%

12 Analysts have issued a sales forecast Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2025 . The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR sales estimate is

$29.3b
Unlock
. This is
2.92% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$31.0b 2.73%
Unlock
, the lowest is
$27.6b 8.70%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $29.5b 0.78%
2025
$29.3b 0.49%
Unlock
2026
$29.7b 1.18%
Unlock
2027
$30.3b 1.89%
Unlock
2028
$31.1b 2.93%
Unlock
2029
$32.3b 3.80%
Unlock

7 Analysts have issued an Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA forecast 2025. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA estimate is

$7.4b
Unlock
. This is
18.73% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$9.2b 1.31%
Unlock
, the lowest is
$6.4b 30.00%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $8.7b 10.86%
2025
$7.4b 15.14%
Unlock
2026
$7.8b 6.22%
Unlock
2027
$8.1b 3.23%
Unlock
2028
$7.8b 3.08%
Unlock
2029
$7.4b 6.06%
Unlock

EBITDA Margin

2024 29.51% 10.15%
2025
25.16% 14.73%
Unlock
2026
26.41% 4.97%
Unlock
2027
26.76% 1.33%
Unlock
2028
25.20% 5.83%
Unlock
2029
22.81% 9.48%
Unlock

6 Takeda Pharmaceutical Co. Ltd. Sponsored ADR Analysts have issued a net profit forecast 2025. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR net profit estimate is

$826m
Unlock
. This is
57.30% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.5b 21.82%
Unlock
, the lowest is
$601m 68.91%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $1.0b 57.33%
2025
$826m 18.59%
Unlock
2026
$1.5b 78.56%
Unlock
2027
$1.8b 21.04%
Unlock
2028
$2.8b 58.23%
Unlock
2029
$3.5b 22.77%
Unlock

Net Margin

2024 3.44% 57.00%
2025
2.81% 18.33%
Unlock
2026
4.97% 76.87%
Unlock
2027
5.90% 18.71%
Unlock
2028
9.07% 53.73%
Unlock
2029
10.73% 18.30%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Mar '24 2025
Estimates
Earnings Per Share $ 0.32 0.26
57.33% 18.75%
P/E 52.28
EV/Sales 2.47

6 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast for earnings per share. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.26
Unlock
. This is
57.38% lower
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.48 21.31%
Unlock
, the lowest is
$0.19 68.85%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.32 57.33%
2025
$0.26 18.75%
Unlock
2026
$0.47 80.77%
Unlock
2027
$0.56 19.15%
Unlock
2028
$0.89 58.93%
Unlock
2029
$1.09 22.47%
Unlock

P/E ratio

Current 22.29 26.82%
2025
52.28 134.54%
Unlock
2026
29.28 43.99%
Unlock
2027
24.19 17.38%
Unlock
2028
15.29 36.79%
Unlock
2029
12.45 18.57%
Unlock

Based on analysts' sales estimates for 2025, the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.40 0.83%
2025
2.47 2.95%
Unlock
2026
2.44 1.17%
Unlock
2027
2.40 1.86%
Unlock
2028
2.33 2.85%
Unlock
2029
2.24 3.66%
Unlock

P/S ratio

Current 1.43 0.59%
2025
1.47 3.00%
Unlock
2026
1.45 1.16%
Unlock
2027
1.43 1.86%
Unlock
2028
1.39 2.84%
Unlock
2029
1.34 3.66%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today